REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company that discovers, develops, and commercializes medicines for the treatment of serious diseases. Its product portfolio includes therapies for conditions such as eye diseases, cancer, and inflammatory diseases. Regeneron operates in various segments, including ophthalmology, oncology, and immunology, serving healthcare providers and patients primarily in the United States and internationally. The company utilizes its proprietary technologies to advance its drug development pipeline and enhance its therapeutic offerings.